IK Investment Partners (“IK”) is pleased to announce that the IK Small Cap I Fund has reached an agreement to acquire APOSAN Dr. Künzer GmbH (“APOSAN” or “the Company”), a leading pharmaceutical homecare company in Germany. Financial terms of the transaction are not disclosed.
APOSAN was founded in 1991 by Dr. Clemens Künzer, with the purpose to service homecare patients through the compounding of individualised infusible and injectable medication. Since then, the company has evolved to an integrated full-range pharmaceutical homecare supplier with its own manufacturing capacities and a dedicated key account management and homecare nurses team to generate and support its growing nationwide patient base. The APOSAN group of companies is organised in three main business segments: pharmaceutical homecare, providing services to patients that require long-term infusion to diseases; classical homecare, providing standard enteral nutrition solutions as well as selected standard medical devices; and ophthalmic injectables. Founder Dr. Clemens Künzer will retain a substantial shareholding in the Company. The broad and experienced management team led going forward by Rainer Schmitz as CEO, Michael Schmitz as CSO and Claudia Vitiello as COO will also become shareholders and invest alongside Dr. Künzer and IK. APOSAN is headquartered in Cologne, Germany, and serves over 10,000 patients per year.